Small molecule · Agonist of 5-hydroxytryptamine (serotonin) receptors · developed by Pulmatrix
PUR3100 is an inhalation powder containing dihydroergotamine (DHE) mesylate, delivered as 500 µg capsules with mannitol, leucine and sodium chloride as excipients. It acts as a broad-spectrum agonist at 5-hydroxytryptamine (serotonin), dopamine and adrenergic receptors.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05351086 | Phase 1 | Healthy | Completed | PULM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Healthy
Updated Oct 25, 2026. Something wrong or missing? Report it on the PULM page.
See PULM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PULM catalysts and pipeline →